Integrated Biopharma Inc
ir.ibiopharma.comIntegrated BioPharma Inc (OTCQX: INBP) is a nutraceutical and pharmaceutical contract manufacturing company that produces dietary supplement and nutraceutical products for third-party customers. Revenue comes primarily from contract manufacturing services, with a secondary contribution from other nutraceutical product sales. The company trades on the OTCQX Best Market under the symbol INBP, a listing it has held since January 22, 2021. Net sales from operations were approximately $54.4 million in FY2025 (fiscal year ended June 30, 2025), up from approximately $50.3 million in FY2024, an increase of roughly $4.0 million. Net income was approximately $808 thousand in FY2025 versus approximately $112 thousand in FY2024. The business operates in a regulatory environment overseen by the FDA and FTC, with product claims for dietary supplements subject to ongoing scrutiny. Margins face pressure from inflation, labor costs, shipping costs, and tariffs, which the company attempts to offset through price increases and higher sales volumes.
Products & Services
Contract-manufactured nutraceutical and dietary supplement products. The company also generates revenue from other nutraceutical business products and services. No specific branded product names are identified in the filing excerpts.
Revenue Model
Transactional revenue from contract manufacturing of nutraceutical and dietary supplement products for third-party customers, supplemented by direct nutraceutical product sales. Net sales were approximately $54.4 million in FY2025 and approximately $50.3 million in FY2024 (fiscal years ended June 30).
Customers & Markets
Third-party customers in the nutraceutical and dietary supplement industry who outsource manufacturing. Revenue mix is dependent on contract manufactured products and other nutraceutical sales. The filing notes that customer order patterns, inventory levels, and consumer confidence affect demand. No specific customer names or concentration percentages are disclosed in the excerpts.
Geographic Exposure
The filing references the United States regulatory environment (FDA, FTC) as the primary operating context. No specific geographic revenue breakdown or international operations are disclosed in the excerpts.
Financial Snapshot
Loading...
